Skip to content
Acting Auditions – Lifestyle
Author:
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
October 1, 2026
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
September 30, 2026
MRT-6160 Enters Phase 2 Study for Sjögren’s Disease
September 8, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2026
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
September 1, 2026
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
August 24, 2026
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
May 20, 2026
1
2
Next Page
→